Abemaciclib induced tumor regression in vivo in xenografts of HR+ breast cancer, with corresponding changes of molecular markers of cell cycle inhibition, including phosphorylation of Rb and TopoIIα expression in tumors from mice administered abemaciclib. Here, RB1 is linked to neoplasm.